KR102824799B1 - 알파-d-갈락토피라노시드 유도체 - Google Patents

알파-d-갈락토피라노시드 유도체 Download PDF

Info

Publication number
KR102824799B1
KR102824799B1 KR1020227009790A KR20227009790A KR102824799B1 KR 102824799 B1 KR102824799 B1 KR 102824799B1 KR 1020227009790 A KR1020227009790 A KR 1020227009790A KR 20227009790 A KR20227009790 A KR 20227009790A KR 102824799 B1 KR102824799 B1 KR 102824799B1
Authority
KR
South Korea
Prior art keywords
triazol
pyran
methyl
hydroxymethyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227009790A
Other languages
English (en)
Korean (ko)
Other versions
KR20220053622A (ko
Inventor
마르틴 볼리
욘 가트필트
코리나 그리소스토미
루보스 레멘
크리슈토프 자거
코르넬리아 춤브룬
Original Assignee
이도르시아 파마슈티컬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이도르시아 파마슈티컬스 리미티드 filed Critical 이도르시아 파마슈티컬스 리미티드
Publication of KR20220053622A publication Critical patent/KR20220053622A/ko
Application granted granted Critical
Publication of KR102824799B1 publication Critical patent/KR102824799B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020227009790A 2019-08-29 2020-08-28 알파-d-갈락토피라노시드 유도체 Active KR102824799B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2019073063 2019-08-29
EPPCT/EP2019/073063 2019-08-29
PCT/EP2020/074121 WO2021038068A1 (en) 2019-08-29 2020-08-28 Alpha-d-galactopyranoside derivatives

Publications (2)

Publication Number Publication Date
KR20220053622A KR20220053622A (ko) 2022-04-29
KR102824799B1 true KR102824799B1 (ko) 2025-06-24

Family

ID=72561746

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227009790A Active KR102824799B1 (ko) 2019-08-29 2020-08-28 알파-d-갈락토피라노시드 유도체

Country Status (22)

Country Link
US (2) US12319672B2 (https=)
EP (1) EP4021904B1 (https=)
JP (1) JP7612669B2 (https=)
KR (1) KR102824799B1 (https=)
CN (1) CN114585619B (https=)
AU (1) AU2020338816B2 (https=)
BR (1) BR112022003562A2 (https=)
CA (1) CA3148365A1 (https=)
ES (1) ES2972551T3 (https=)
HR (1) HRP20240297T1 (https=)
HU (1) HUE066221T2 (https=)
IL (1) IL290815B2 (https=)
MA (1) MA57000B1 (https=)
MX (1) MX2022002339A (https=)
MY (1) MY207787A (https=)
PH (1) PH12022550436A1 (https=)
PL (1) PL4021904T3 (https=)
RS (1) RS65294B1 (https=)
SA (1) SA522431777B1 (https=)
TW (1) TWI864085B (https=)
UA (1) UA129205C2 (https=)
WO (1) WO2021038068A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
WO2021028323A1 (en) 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
US12312362B2 (en) 2020-10-06 2025-05-27 Idorsia Pharmaceuticals Ltd Spiro derivatives of Alpha-D-galactopyranosides
EP4237419A1 (en) 2020-11-02 2023-09-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
CN116806219A (zh) * 2021-02-09 2023-09-26 爱杜西亚药品有限公司 羟基杂环烷-氨甲酰基衍生物
RS67032B1 (sr) * 2021-03-03 2025-08-29 Idorsia Pharmaceuticals Ltd Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom
US20240287121A1 (en) * 2021-05-28 2024-08-29 Glycomimetics, Inc. Galectin-3 inhibiting c-glycoside oximes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016120403A1 (en) 2015-01-30 2016-08-04 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
DK2906227T3 (en) 2012-10-10 2018-12-10 Galectin Therapeutics Inc GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy
CN104755088A (zh) 2012-10-31 2015-07-01 格莱克特生物技术公司 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
PL3456717T3 (pl) 2015-07-06 2021-10-25 Gilead Sciences, Inc. Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
CA3025867A1 (en) 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
EP3621973A4 (en) 2017-05-12 2021-10-27 Galectin Sciences, LLC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF
KR20200015528A (ko) 2017-05-12 2020-02-12 갈랙틴 사이언시즈, 엘엘씨 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
CA3080128A1 (en) 2017-10-31 2019-05-09 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
CN113286632A (zh) 2018-10-15 2021-08-20 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂前药
JP2022508720A (ja) 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤
WO2020104335A1 (en) 2018-11-21 2020-05-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US12269819B2 (en) 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
JP7674276B2 (ja) 2019-07-03 2025-05-09 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤
WO2021004940A1 (en) 2019-07-05 2021-01-14 Galecto Biotech Ab Novel galactoside inhibitor of galectins
WO2021028323A1 (en) 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
US12312362B2 (en) 2020-10-06 2025-05-27 Idorsia Pharmaceuticals Ltd Spiro derivatives of Alpha-D-galactopyranosides
EP4237419A1 (en) 2020-11-02 2023-09-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
CN116806219A (zh) 2021-02-09 2023-09-26 爱杜西亚药品有限公司 羟基杂环烷-氨甲酰基衍生物
RS67032B1 (sr) 2021-03-03 2025-08-29 Idorsia Pharmaceuticals Ltd Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016120403A1 (en) 2015-01-30 2016-08-04 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins

Also Published As

Publication number Publication date
IL290815A (en) 2022-04-01
MA57000B1 (fr) 2024-03-29
CN114585619B (zh) 2024-09-27
SA522431777B1 (ar) 2024-04-30
TWI864085B (zh) 2024-12-01
IL290815B2 (en) 2025-08-01
ES2972551T3 (es) 2024-06-13
US20220281855A1 (en) 2022-09-08
MY207787A (en) 2025-03-19
AU2020338816A1 (en) 2022-04-14
EP4021904C0 (en) 2024-01-03
EP4021904A1 (en) 2022-07-06
UA129205C2 (uk) 2025-02-05
RS65294B1 (sr) 2024-04-30
WO2021038068A1 (en) 2021-03-04
US20250257056A1 (en) 2025-08-14
PL4021904T3 (pl) 2024-05-13
HUE066221T2 (hu) 2024-07-28
IL290815B1 (en) 2025-04-01
PH12022550436A1 (en) 2022-12-19
KR20220053622A (ko) 2022-04-29
MX2022002339A (es) 2022-04-06
JP7612669B2 (ja) 2025-01-14
HRP20240297T1 (hr) 2024-05-10
CN114585619A (zh) 2022-06-03
EP4021904B1 (en) 2024-01-03
TW202122092A (zh) 2021-06-16
JP2022546029A (ja) 2022-11-02
AU2020338816B2 (en) 2026-01-08
BR112022003562A2 (pt) 2022-05-24
CA3148365A1 (en) 2021-03-04
US12319672B2 (en) 2025-06-03

Similar Documents

Publication Publication Date Title
KR102824799B1 (ko) 알파-d-갈락토피라노시드 유도체
KR102832308B1 (ko) 2-히드록시시클로알칸-1-카르바모일 유도체
KR102863667B1 (ko) (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
JP7757399B2 (ja) アルファ－ｄ－ガラクトピラノシドのスピロ誘導体
CA3207214A1 (en) Hydroxyheterocycloalkane-carbamoyl derivatives
HK40072885A (en) Alpha-d-galactopyranoside derivatives
HK40072885B (en) Alpha-d-galactopyranoside derivatives
EA048563B1 (ru) Производные альфа-d-галактопиранозида

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220323

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250407

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250620

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250620

End annual number: 3

Start annual number: 1

PG1601 Publication of registration